Bone mineral density (BMD) improves by 2-3% in HIV+ adults who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). The extent to which these increases can be augmented with concomitant bisphosphonate (BP) use is unknown.
We pooled data from two prospective 144-week, Phase 3 studies of HIV-infected adults virologically suppressed on TDF-based regimens who switched to elvitegravir, cobicistat, and emtricitabine (E/C/F) co-formulated with TAF. In adults with clinically significant low BMD by dual energy x-ray absorptiometry (T-score ≤-2.0 at lumbar spine, femoral neck, or total hip) at baseline (BL), we compared the percentage change in BMD and change in T-score at the lumbar spine and total hip in BP users v. non-users over 144 weeks. We estimated the effect of BP use on bone outcomes independent of age, race, sex, BMI, current smoking status, and BL BMD with linear regression.
Of 1117 adults enrolled who switched from TDF to TAF, 214 (19%) had clinically significant low BL BMD, of whom 43% (93/214) had osteoporosis. Over 144 weeks, 30/214 (14%) reported using BPs with median (Q1, Q3) use of 754 (425, 1032) days. At BL, BP users were more likely to be women (33% vs 12%), to be current smokers (40% vs 23%), and to have lower spine and hip BMD. At 144 weeks, spine BMD increased by the mean (Q1, Q3) of 5.1% (4.0, 8.3) (p<0.001) in the BP users and 2.6% (-0.5, 5.4) (p<0.001) in the non-BP users (between group p=0.002). In the hip, median (Q1, Q3) BMD increased in BP users [4.0% (1.2, 6.7)] (p<0.001) and non-users [2.3% (0.9, 4.4)] (p<0.001) with no difference between the groups (p=0.29). In multivariable models, compared to non-users, BP users tended to have greater increase in lumbar spine BMD [2.6% (95% CI: -0.3, 5.4); p=0.08], corresponding to a 0.21 (95% CI:-0.01, 0.42; p=0.06) T-score increase. At the hip, the magnitude of the increase in BMD and T-score was similar in BP vs non-users (p>0.80).
Switching from TDF to TAF improved BMD over 144 weeks in HIV+ adults with low BMD. In this cohort, concomitant BP use augmented these gains at the spine but not the hip. Future controlled studies are required to confirm these findings and examine whether a sequential strategy of TDF switching followed by BP use would result in improved BMD gains compared to a combined strategy of concomitant TDF switching plus BP use.